Fexlamose
Investigational drug
Fexlamose is an investigational new drug that is being developed by Aer Therapeutics for the treatment of chronic obstructive pulmonary disease. It is mucolytic agent that contains a thiol linked to a saccharide that undergoes thiol, disulfide exchange with mucin disulfide bridges thereby breaking those bonds between mucin subunits and reducing the viscosity of mucin.
Sources and credits
This article is adapted from the Wikipedia article “Fexlamose”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Images, from Wikimedia Commons:
- Fexlamose.svg by Boghog, CC0
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.